(Q46202380)

20 December 2017

title

Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms (English)

1 reference

20 December 2017

0 references

1 reference

M Poyurovsky

1

1 reference

20 December 2017

I Glick

series ordinal

2

1 reference

20 December 2017

L M Koran

series ordinal

3

1 reference

20 December 2017

language of work or name

English

0 references

publication date

12 December 2008

1 reference

20 December 2017

Journal of Psychopharmacology

published in

1 reference

20 December 2017

volume

24

1 reference

20 December 2017

page(s)

861-866

1 reference

20 December 2017

issue

6

1 reference

20 December 2017

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

Glutamatergic dysfunction in OCD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

Obsessive-compulsive symptoms and positive, negative, and depressive symptoms in patients with recent-onset schizophrenic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

Detection and management of comorbidity in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

Effectiveness of lamotrigine in bipolar disorder in a clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

Obsessive-Compulsive Disorder in Adolescent Schizophrenia Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

Treatment non-response in OCD: methodological issues and operational definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

Obsessive-compulsive disorder in elderly schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

Familial aggregation of schizophrenia-spectrum disorders and obsessive-compulsive associated disorders in schizophrenia probands with and without OCD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

Memantine for treatment-resistant OCD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

Obsessive-compulsive disorder in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

A magnetic resonance spectroscopy investigation of obsessive-compulsive disorder and anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: A double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108099215

21 January 2018

Identifiers

DOI

10.1177/0269881108099215

1 reference

20 December 2017

PubMed ID

19074541

1 reference

20 December 2017